Steno Diabetes Center North Denmark
Aalborg, 9000, Denmark
NCT Number: NCT06134934
This feasibility study will evaluate the feasibility of two telemonitoring designs for non-insulin treated T2D patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Aalborg, 9000, Denmark
Background: Maintaining optimal glycaemic control in type 2 diabetes (T2D) is difficult. Telemedicine has potential to support poorly controlled people with T2D in the achievement of glycaemic control if the telemedicine solution includes a telemonitoring component. However, only few telemonitoring solutions for non-insulin treated T2D exist. Therefore, the aim of this feasibility study is to evaluate the feasibility of two telemonitoring intervention designs for non-insulin treated T2D patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial.
Method: The trial will be conducted as a three-month randomized feasibility study in four municipalities in North Denmark with 15 participants from each municipality. Two different telemonitoring intervention designs will be tested. One intervention will include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health. The second intervention will include an identical setup but with the addition of blood pressure and activity monitoring. Two municipalities will be allocated to one intervention design, whereas the other two municipalities will be allocated to the second intervention design. Qualitative interviews with participants and clinicians will be conducted to gain insight into their experiences with and acceptance of the intervention designs and trial procedures (e.g., blood sampling and questionnaires). In addition, differences in direct intervention costs between the two alternative interventions will be evaluated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity.
This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health.
Time frame: 3 months
Qualitative interviews will be conducted with selected participants and HCPs to gain deeper insight into the participants and HCPs' experiences and acceptability with the two different telemonitoring intervention designs and the trial procedures.
Time frame: 1 month
Number (whole) of people agreeing to receive participant information letter about the study.
Time frame: 1 month
Proportion (percentage) of people agreeing to receive participant information letter about the study.
Time frame: 1 month
Number (whole) of eligible participants who agree to participate.
Time frame: 1 month
Proportion (percentage) of eligible participants who agree to participate.
Time frame: 1 month
Potential inequalities regarding recruitment feasibility assessed by comparing those who accepted participation to those who declined with respect to demographic data on age (years), sex (m/f/other), ethnicity (danish/other western/not western), municipality, setting (health care center versus home health care setting), and HbA1c levels (mmol/L).
Time frame: 3 months
Number (whole) of participants withdrawing from the trial.
Time frame: 3 months
Proportion (percentage) of participants withdrawing from the trial.
Time frame: 3 months
Timepoint(s) for withdrawal.
Time frame: 3 months
Reasons of discontinuation of the trial.
Time frame: 3 months
Potential inequalities regarding retention feasibility assessed by comparing those who retented participation to those who withdrawal with respect to demographic data on age (years), sex (m/f/other), ethnicity (danish/other western/not western), municipality, setting (health care center versus home health care setting), and HbA1c levels (mmol/L).
Time frame: At baseline (T0) and 3 months (T1)
The respons rate for PAID-5 at baseline and at 3 months, respectively.
Time frame: At baseline (T0) and 3 months (T1)
The respons rate for SF-12v2 at baseline and at 3 months, respectively.
Time frame: At baseline (T0) and 3 months (T1)
The respons rate for WHO-5 at baseline and at 3 months, respectively.
Time frame: At baseline (T0) and 3 months (T1)
The respons rate for PAM at baseline and at 3 months, respectively.
Time frame: At baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3)
Explore through qualitative interviews whether there are any analysis challenges or uncertainties in the clinical workflow with regard to the blood sampling schedule.
Time frame: At baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3)
Number and proportion of the participants who completes the blood sampling at baseline, 3 months, 6 months, and 12 months, respectively.
Time frame: 12 months
Differences in direct intervention costs between the two alternatives. Resource categories are comprised of equipment and time spent on monitoring, time spent training patients in using the equipment, and potential additional training for community nurses. Resources will be evaluated as prices paid and hourly wages and represented as equivalent annual costs in 2023 prices.
Aalborg University Hospital
Other
TeleCare North Diabetes: A Feasibility Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05198765
Body Weight, Diabetes Mellitus
Minneapolis, Minnesota, United States
View Trial DetailsNCT02710370
Body Weight, Diabetes Mellitus
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06641765
Autoimmune Diseases, Continuous Glucose Monitoring
Copenhagen, Denmark
View Trial DetailsNCT00005487
Arterial Occlusive Diseases, Arteriosclerosis
View Trial Details